We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GW Pharma (GWPH) Q3 Earnings: Is a Turnaround in the Cards?
Read MoreHide Full Article
GW Pharmaceuticals plc is scheduled to report its fiscal third-quarter 2018 results on Aug 7, after market close.
GW Pharma’s share price has decreased 1.1% so far this year compared with the industry’s gain of 10.6% in the same time frame.
Factors at Play
GW Pharma derives revenues from the sale of its sole commercial drug, Sativex, which is marketed outside the United States for the treatment of spasticity due to multiple sclerosis. The company is planning to conduct a pivotal study for approval of the drug in the United States. The drug is expected to continue the growth trend of the past several quarters this time around as well.
In June, the FDA approved its lead cannabinoid pipeline candidate, Epidiolex for the treatment of Lennox-Gastaut syndrome (“LGS”) and Dravet syndrome. The candidate is under review in Europe. Although an impact on revenues is unlikely, the company is gearing up for a launch, which will likely increase operating expenses.
Moreover, two phase III studies evaluating Epidiolex in tuberous sclerosis complex and Dravet syndrome are ongoing. The company is also focused on developing several new formulations for the drug. These are likely to increase research & development expense. However, part B of a phase II/III study evaluating Epidiolex ininfantile spasms is unlikely to commence based on currently available data from part A of the study. The company may provide an update on the third-quarter earnings call.
The company is developing Epidiolex as monotherapy or in combination for treatingother indication. The company is planning to initiate a pivotal and a mid-stage studies.
Investors are expected to focus on the company’s commercialization plan for Epidiolex and update on pipeline progress in the upcoming earnings release.
Surprise History
GW Pharma’s performance over the last four quarters has been disappointing, with the company missing the Zacks Consensus Estimate in all the last four quarters. The average negative surprise over the last four quarters is 26.48%.
Earnings Whispers
Our proven model does not show conclusively that GW Pharma is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: GW Pharma has an Earnings ESP of 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of $2.39. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: GW Pharma sports a Zacks Rank #1, which increases the predictive power of ESP. However, the company’s 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Omeros (OMER - Free Report) has an Earnings ESP of +2.17% and a Zacks Rank #3. The company is scheduled to release second-quarter results on Aug 14.
Coherus BioSciences (CHRS - Free Report) has an Earnings ESP of +7.91% and currently carries a Zacks Rank #3. The company is scheduled to release second-quarter results on Aug 8.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
GW Pharma (GWPH) Q3 Earnings: Is a Turnaround in the Cards?
GW Pharmaceuticals plc is scheduled to report its fiscal third-quarter 2018 results on Aug 7, after market close.
GW Pharma’s share price has decreased 1.1% so far this year compared with the industry’s gain of 10.6% in the same time frame.
Factors at Play
GW Pharma derives revenues from the sale of its sole commercial drug, Sativex, which is marketed outside the United States for the treatment of spasticity due to multiple sclerosis. The company is planning to conduct a pivotal study for approval of the drug in the United States. The drug is expected to continue the growth trend of the past several quarters this time around as well.
In June, the FDA approved its lead cannabinoid pipeline candidate, Epidiolex for the treatment of Lennox-Gastaut syndrome (“LGS”) and Dravet syndrome. The candidate is under review in Europe. Although an impact on revenues is unlikely, the company is gearing up for a launch, which will likely increase operating expenses.
Moreover, two phase III studies evaluating Epidiolex in tuberous sclerosis complex and Dravet syndrome are ongoing. The company is also focused on developing several new formulations for the drug. These are likely to increase research & development expense. However, part B of a phase II/III study evaluating Epidiolex ininfantile spasms is unlikely to commence based on currently available data from part A of the study. The company may provide an update on the third-quarter earnings call.
The company is developing Epidiolex as monotherapy or in combination for treatingother indication. The company is planning to initiate a pivotal and a mid-stage studies.
Investors are expected to focus on the company’s commercialization plan for Epidiolex and update on pipeline progress in the upcoming earnings release.
Surprise History
GW Pharma’s performance over the last four quarters has been disappointing, with the company missing the Zacks Consensus Estimate in all the last four quarters. The average negative surprise over the last four quarters is 26.48%.
Earnings Whispers
Our proven model does not show conclusively that GW Pharma is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: GW Pharma has an Earnings ESP of 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of $2.39. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: GW Pharma sports a Zacks Rank #1, which increases the predictive power of ESP. However, the company’s 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
GW Pharmaceuticals PLC Price and EPS Surprise
GW Pharmaceuticals PLC Price and EPS Surprise | GW Pharmaceuticals PLC Quote
Stocks That Warrant a Look
Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
BioLife Solutions (BLFS - Free Report) has an Earnings ESP of +50% and a Zacks Rank #2. The company is scheduled to release second-quarter results on Aug 9. You can see the complete list of today’s Zacks #1 Rank stocks here.
Omeros (OMER - Free Report) has an Earnings ESP of +2.17% and a Zacks Rank #3. The company is scheduled to release second-quarter results on Aug 14.
Coherus BioSciences (CHRS - Free Report) has an Earnings ESP of +7.91% and currently carries a Zacks Rank #3. The company is scheduled to release second-quarter results on Aug 8.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>